{"id":"hz-su-vaccine-gsk1437173a","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site erythema"},{"rate":null,"effect":"Injection site pain"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GSK1437173A is a subunit vaccine containing recombinant VZV glycoprotein E (gE) combined with the AS01B adjuvant system, which enhances both cellular and humoral immune responses. The vaccine primes T-cell and B-cell immunity against VZV, reducing the risk of reactivation and the severity of herpes zoster disease in immunocompetent older populations.","oneSentence":"This recombinant zoster vaccine stimulates immune responses against varicella-zoster virus (VZV) to prevent herpes zoster (shingles) and post-herpetic neuralgia in older adults.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:45:38.062Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of herpes zoster (shingles) in adults aged 50 years and older"},{"name":"Prevention of post-herpetic neuralgia in adults aged 50 years and older"}]},"trialDetails":[{"nctId":"NCT04006808","phase":"PHASE1, PHASE2","title":"A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2019-10-25","conditions":"Herpes Zoster","enrollment":184},{"nctId":"NCT02723773","phase":"PHASE3","title":"A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-04-16","conditions":"Herpes Zoster, Herpes Zoster Vaccine","enrollment":7539},{"nctId":"NCT04091451","phase":"PHASE3","title":"Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-09-17","conditions":"Herpes Zoster","enrollment":1430},{"nctId":"NCT04176939","phase":"PHASE3","title":"A Study to Test GlaxoSmithKline's (GSK) Herpes Zoster (HZ) Subunit Vaccine's Long-term Immune Response in Previously Vaccinated Kidney Transplant Adults and Then to Test if 2 Additional Doses of the Vaccine Are Safe and Able to Generate an Immune Response","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-12-09","conditions":"Herpes Zoster","enrollment":68},{"nctId":"NCT02735915","phase":"PHASE3","title":"Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-04-11","conditions":"Herpes Zoster","enrollment":70},{"nctId":"NCT03439657","phase":"PHASE3","title":"Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-04-12","conditions":"Herpes Zoster","enrollment":913},{"nctId":"NCT02075515","phase":"PHASE3","title":"Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-08-13","conditions":"Herpes Zoster, Herpes Zoster Vaccine","enrollment":651},{"nctId":"NCT01798056","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-03-06","conditions":"Herpes Zoster, Herpes Zoster Vaccine","enrollment":237},{"nctId":"NCT02690207","phase":"PHASE3","title":"Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-03-16","conditions":"Herpes Zoster","enrollment":8687},{"nctId":"NCT02979639","phase":"PHASE3","title":"Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-01-16","conditions":"Herpes Zoster","enrollment":404},{"nctId":"NCT01777321","phase":"PHASE3","title":"Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Intramuscularly in Adults Aged ≥50 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-06-17","conditions":"Herpes Zoster","enrollment":60},{"nctId":"NCT01751165","phase":"PHASE3","title":"Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-03-12","conditions":"Herpes Zoster","enrollment":354},{"nctId":"NCT01827839","phase":"PHASE3","title":"Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-06-10","conditions":"Herpes Zoster","enrollment":96},{"nctId":"NCT02581410","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-12-15","conditions":"Herpes Zoster","enrollment":430},{"nctId":"NCT02058589","phase":"PHASE3","title":"Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults 18 Years of Age or Older With Renal Transplant","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-03-20","conditions":"Herpes Zoster","enrollment":265},{"nctId":"NCT01767467","phase":"PHASE3","title":"Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-03-01","conditions":"Herpes Zoster","enrollment":568},{"nctId":"NCT01954251","phase":"PHASE3","title":"Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-10-03","conditions":"Herpes Zoster","enrollment":829},{"nctId":"NCT01165203","phase":"PHASE2","title":"Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09-30","conditions":"Herpes Zoster","enrollment":123},{"nctId":"NCT02052596","phase":"PHASE3","title":"Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-02-07","conditions":"Herpes Zoster","enrollment":935}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HZ/su vaccine GSK1437173A","genericName":"HZ/su vaccine GSK1437173A","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"This recombinant zoster vaccine stimulates immune responses against varicella-zoster virus (VZV) to prevent herpes zoster (shingles) and post-herpetic neuralgia in older adults. Used for Prevention of herpes zoster (shingles) in adults aged 50 years and older, Prevention of post-herpetic neuralgia in adults aged 50 years and older.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}